NASDAQ:RDHL Redhill Biopharma (RDHL) Stock Price, News & Analysis $1.34 +0.01 (+0.68%) As of 03:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Redhill Biopharma Stock (NASDAQ:RDHL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Redhill Biopharma alerts:Sign Up Key Stats Today's Range$1.29▼$1.3650-Day Range$1.16▼$2.4252-Week Range$1.06▼$12.50Volume17,732 shsAverage Volume302,010 shsMarket Capitalization$3.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. Read More Receive RDHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Redhill Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RDHL Stock News HeadlinesRedHill awarded $1.82M in legal costs and expenses in action against KukboAugust 20, 2025 | msn.comRedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment WinAugust 20, 2025 | prnewswire.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 28 at 2:00 AM | InvestorPlace (Ad)RedHill Biopharma receives Talicia licensing payments totaling $1.1MAugust 19, 2025 | msn.comRedHill Received Talicia® Licensing Payments Totaling $1.1 MillionAugust 18, 2025 | prnewswire.comRedHill Biopharma Granted Nasdaq Compliance ExtensionAugust 14, 2025 | msn.comRedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's DiseaseJuly 21, 2025 | prnewswire.comRDHL - Redhill Biopharma Ltd ADR Trailing Returns - MorningstarJuly 18, 2025 | morningstar.comMSee More Headlines RDHL Stock Analysis - Frequently Asked Questions How have RDHL shares performed this year? Redhill Biopharma's stock was trading at $6.21 at the start of the year. Since then, RDHL stock has decreased by 79.0% and is now trading at $1.3050. How were Redhill Biopharma's earnings last quarter? Redhill Biopharma Ltd. (NASDAQ:RDHL) posted its earnings results on Tuesday, November, 30th. The biotechnology company reported ($500.00) earnings per share for the quarter, missing analysts' consensus estimates of ($480.00) by $20.00. The biotechnology company earned $21.61 million during the quarter, compared to analysts' expectations of $23.41 million. When did Redhill Biopharma's stock split? Redhill Biopharma shares reverse split on Tuesday, August 20th 2024.The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Redhill Biopharma? Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Redhill Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Redhill Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CymaBay Therapeutics (CBAY) and AbbVie (ABBV). Company Calendar Last Earnings11/30/2021Today8/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RDHL Previous SymbolASX:RDH CIK1553846 Webwww.redhillbio.com Phone972-3541-3131Fax972-3541-3144Employees210Year Founded2009Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.37 Sales & Book Value Annual Sales$8.04 million Price / Sales0.37 Cash FlowN/A Price / Cash FlowN/A Book Value($3.66) per share Price / Book-0.36Miscellaneous Outstanding Shares2,300,000Free Float2,139,000Market Cap$3.00 million OptionableNo Data Beta4.18 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:RDHL) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.